Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia.
Molecular testing for the BCR-ABL1 fusion gene by real time quantitative polymerase chain reaction (RT-qPCR) is the most sensitive routine approach for monitoring the response to therapy of patients with chronic myeloid leukaemia. In the context of tyrosine kinase inhibitor (TKI) therapy, the techni...
Príomhchruthaitheoirí: | Foroni, L, Wilson, G, Gerrard, G, Mason, J, Grimwade, D, White, H, de Castro, D, Austin, S, Awan, A, Burt, E, Clench, T, Farruggia, J, Hancock, J, Irvine, A, Kizilors, A, Langabeer, S, Milner, B, Nickless, G, Schuh, A, Sproul, A, Wang, L, Wickham, C, Cross, N |
---|---|
Formáid: | Journal article |
Teanga: | English |
Foilsithe / Cruthaithe: |
2011
|
Míreanna comhchosúla
Míreanna comhchosúla
-
Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK
de réir: Cross, N, et al.
Foilsithe / Cruthaithe: (2018) -
Sequential quantitative minimal residual disease in BCR-ABL positive acute lymphoblastic leukaemia: Differential observations between major and minor fusion gene rearrangements and variation due to source material
de réir: Gerrard, G, et al.
Foilsithe / Cruthaithe: (2004) -
No Benefit of BCR-ABL1 Screening in Polycythemia
de réir: STEPHEN E. LANGABEER
Foilsithe / Cruthaithe: (2016-07-01) -
Targeting BCR-ABL1-positive leukaemias: a review article
de réir: Steven Leak, et al.
Foilsithe / Cruthaithe: (2023-01-01) -
The FABD domain is critical for the oncogenicity of BCR/ABL in chronic myeloid leukaemia
de réir: Renren Zheng, et al.
Foilsithe / Cruthaithe: (2024-06-01)